Nonclinical precedent Request an invite

Gardasil: animal efficacy model or human cells?

human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant · HPV 6/11/16/18 L1 VLPs
Efficacy evidence
Immunogenicity in rhesus macaques, chimpanzees and African green monkeys; neutralising antibodies; no HPV challenge model
“In each of the 3 non-human primate species tested, the intramuscular administration of Gardasil, or it’s monovalent components, was found to elicit immune responses resulting in production of antibodies against the HPV VLP types present in the vaccine.”
✓ VerifiedEMA assessment report, p. 7Source ↗
Why that model
No animal model of human papillomavirus infection; species-specific papillomaviruses used instead
“There is no animal model for human papillomavirus infection, however there are other species-specific papillomaviruses that have been studied in animal models.”
✓ VerifiedEMA assessment report, p. 7Source ↗
Reviewer's view of the efficacy data
Species-specific models support vaccination; serum transfer of protection suggests humoral-mediated efficacy
“Studies in animal models with species-specific papillomaviruses have demonstrated the possibility to vaccinate against infection and development of tumour lesions using virus-like particles formed by recombinant viral capsid proteins. Protection could be transferred with serum, suggesting that the efficacy of Gardasil is mediated by development of humoral immune response.”
✓ VerifiedEMA assessment report, p. 37Source ↗

Same question, other vaccines

Arexvy

respiratory syncytial virus vaccine, adjuvanted (AS01E) · RSV preF3; TLR4 (AS01E adjuvant)
Immunogenicity of RSVPreF3 with or without AS01 in naive mice (neutralising antibodies, CD4+/CD8+ T cells); no challenge model

Cervarix

human papillomavirus bivalent (types 16, 18) vaccine, recombinant, AS04-adjuvanted · HPV 16/18 L1 VLPs; TLR4 (AS04 adjuvant)
Immunogenicity in mice and rhesus monkeys (AS04 superior to aluminium alone); no protection model

Cyfendus

anthrax vaccine adsorbed, adjuvanted · B. anthracis PA; TLR9 (CpG 7909 adjuvant)
Guinea pig and cynomolgus macaque lethal aerosolized B. anthracis spore challenge after two IM vaccinations

Fendrix

hepatitis B vaccine (rDNA), AS04C-adjuvanted · HBsAg VLPs; TLR4 (AS04C adjuvant)
Immunogenicity in mice: HBsAg with AS04C more immunogenic than with alum

Flublok

influenza vaccine, recombinant hemagglutinin · Influenza HA
Mouse immunogenicity (HAI and neutralizing antibodies) with monovalent rH3 and trivalent RIV3; no challenge studies

Gardasil 9

human papillomavirus 9-valent vaccine, recombinant · HPV 9-valent L1 VLPs
Immunogenicity in rhesus macaques (non-GLP): antibodies to all 9 HPV types; no protection model

HBVaxPro

hepatitis B vaccine (rDNA) · HBsAg VLPs
C3H mouse potency (ED50) testing versus the licensed thiomersal-containing vaccine

Heplisav-B

hepatitis B vaccine (recombinant), adjuvanted · HBsAg; TLR9 (CpG 1018 adjuvant)
Anti-HBsAg immunogenicity of the adjuvanted vaccine in mice, rats and baboons

Mosquirix

RTS,S/AS01 malaria vaccine · P. falciparum CSP-HBsAg (RTS,S) VLPs; TLR4 (AS01 adjuvant)
Immunogenicity in mice and monkeys (3 IM doses, days 0, 14, 28)

Nuvaxovid

COVID-19 vaccine, recombinant spike protein nanoparticle, Matrix-M-adjuvanted · SARS-CoV-2 spike (nanoparticle)
SARS-CoV-2 live-virus challenge in mice, hamsters, cynomolgus and rhesus macaques

PreHevbrio

hepatitis B vaccine (recombinant), 3-antigen · HBsAg S/pre-S1/pre-S2 VLPs
Immunogenicity in mice and rats; no challenge model

Shingrix

zoster vaccine recombinant, AS01B-adjuvanted · VZV glycoprotein E; TLR4 (AS01B adjuvant)
Immunogenicity (cellular and humoral anti-gE) in mice

Summary across all 13 vaccines →